Related Experiment Video

Updated: Feb 3, 2026

Mesocosm-Scale Constructed Wetland Design for Wastewater Treatment
08:24

Mesocosm-Scale Constructed Wetland Design for Wastewater Treatment

Published on: May 2, 2025

1.0K

Increased CD74 binding and EAE treatment efficacy of a modified DRα1 molecular construct

Roberto Meza-Romero1,2,3, Gil Benedek1,2,3,4, Grant Gerstner1,3

  • 1Neuroimmunology Research, Research Service R&D31, VA Portland Health Care System, 3710 SW US Veterans Hospital Rd, Portland, OR, 97239, USA.

Metabolic Brain Disease
|October 25, 2018
PubMed

Insights

A modified DRα1-MOG-35-55 construct (DRhQ) shows enhanced binding to CD74, effectively blocking inflammatory factors. This improved therapy demonstrated increased efficacy in treating experimental autoimmune encephalomyelitis, a model for multiple sclerosis.

Area of Science:

  • Neuroimmunology
  • Molecular Medicine

Background:

  • Multiple sclerosis (MS) is a CNS disease characterized by inflammation, demyelination, and degeneration.
  • Macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT) exacerbate MS inflammation via CD74 receptor interaction.
  • Targeting the MIF-CD74 interaction is crucial for developing novel MS therapeutics.

Purpose of the Study:

  • To investigate the therapeutic potential of a modified DRα1-MOG-35-55 construct with enhanced CD74 binding.
  • To evaluate the efficacy of the modified construct in blocking inflammatory factor interaction and signaling pathways.
  • To assess the therapeutic activity of the modified construct in a mouse model of MS.

Main Methods:

  • Engineered DRα1-MOG-35-55 constructs with a single amino acid substitution (L50Q), creating DRhQ (human) and DRmQ (mouse).
  • Assessed binding affinity of DRhQ to CD74 and its capacity to inhibit MIF and D-DT binding.
  • Evaluated the inhibition of pERK1/2 signaling pathway activation.
  • Tested the therapeutic efficacy of DRhQ in a mouse model of experimental autoimmune encephalomyelitis (EAE).

Main Results:

  • The L50Q substitution in DRhQ significantly increased affinity for CD74 compared to the original construct.
  • DRhQ demonstrated a greater ability to block MIF binding and inhibit pERK1/2 signaling.
  • DRhQ exhibited enhanced therapeutic activity in mice with EAE, reducing disease severity.
  • Increased binding affinity to CD74 correlated with improved biological potency.

Conclusions:

  • The modified DRhQ construct offers a promising therapeutic strategy for MS by enhancing CD74 binding and blocking key inflammatory mediators.
  • Binding affinity to CD74 serves as a reliable indicator of the biological potency of DRhQ.
  • DRhQ holds potential for clinical application in MS and other inflammatory diseases driven by MIF and D-DT.
Keywords:
CD74D-dopachrome tautomeraseEAEMIFMultiple sclerosispERK1/2

More Related Videos

A Modified Technique for Arteriovenous Fistula Construction in Rabbits05:00

A Modified Technique for Arteriovenous Fistula Construction in Rabbits

Published on: February 10, 2023

1.8K
Sequential Salt Extractions for the Analysis of Bulk Chromatin Binding Properties of Chromatin Modifying Complexes07:41

Sequential Salt Extractions for the Analysis of Bulk Chromatin Binding Properties of Chromatin Modifying Complexes

Published on: October 2, 2017

8.9K

Related Concept Videos

Self-Efficacy01:29

Self-Efficacy

Self-efficacy is the belief in one's capacity to organize and execute actions necessary to manage prospective situations. This belief significantly influences how individuals approach goals, tasks, and challenges across different domains of life.Psychological and Educational ImpactsIndividuals with strong self-efficacy are more resilient in the face of difficulties. They are more likely to adopt effective problem-solving strategies, persist through obstacles, and regulate emotions such as...
227
Molecular Orbital Theory I02:35

Molecular Orbital Theory I

Overview of Molecular Orbital Theory
47.5K
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
15.1K
Increasing Function01:18

Increasing Function

An increasing function exhibits a rise in output values as input values increase. This behavior is depicted graphically as a curve or line that slopes upward from left to right. Such a function satisfies the condition that if x1 < x2, then f(x1) < f(x2), indicating that the function values grow with increasing inputs. This concept is fundamental in understanding growth trends across various domains, such as population dynamics, financial investments, or resource consumption.The...
394
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.6K
Increased Body Temperature01:25

Increased Body Temperature

A body temperature above  38°C  (100.4 °F) is known as fever or pyrexia, and a person with fever is termed 'febrile.' Typically, the hypothalamus, a part of the brain that acts as the body's thermostat, regulates body temperature through a thermoregulatory setpoint. It receives signals from cold and warm thermal receptors throughout the body and adjusts the body's temperature accordingly. Fever occurs when this hypothalamic setpoint is altered, usually in...
7.5K